VPC News

The Vancouver Prostate Centre is proud to highlight new findings from the GUNS trial, an adaptive neoadjuvant study designed for men with high-volume, high-grade prostate cancer. Led by Dr. Martin E. Gleave, CM, MD, FRCSC, FACS, British Columbia Leadership Chair, Distinguished Professor, and...

Researchers at the Vancouver Prostate Centre led a national multicentre study demonstrating that circulating tumour DNA (ctDNA) testing can help identify patients with metastatic urothelial carcinoma who may benefit from FGFR-targeted therapies. The study, Prospective multicenter study of ctDNA...

Early-stage, low-grade bladder cancer is often described as “low risk,” yet a substantial proportion of patients experience recurrences that remain difficult to predict using conventional clinical criteria. Traditional risk assessment, such as the International Bladder Cancer Group (IBCG) guidelines...

The Vancouver Prostate Centre is proud to announce that Dr. Nada Lallous, Assistant Professor, UBC Faculty of Medicine, has been selected as a delegate for Science Meets Parliament BC 2026. Science Meets Parliament BC is a prestigious national initiative that brings together researchers and...

Dr. Alex Wyatt and his research team at the Vancouver Prostate Centre (VPC) have published a new study in Clinical Cancer Research examining the impact of radioligand therapy (RLT) in metastatic castration-resistant prostate cancer (mCRPC). The work was led by PhD student Asli Munzur, who presented...

Relax your tight end — a memorable Super Bowl ad reminding men to pay attention to their health! Watch here: https://youtu.be/lMTcZb48aVU

The Vancouver Prostate Centre (VPC) is pleased to share that the M. H. Mohseni Institute of Urologic Sciences (MIUS) has officially launched its presence on LinkedIn as a platform for sharing research highlights, institute updates, and collaborative opportunities. The new MIUS LinkedIn page will...

The Vancouver Prostate Centre (VPC) is pleased to announce that Dr. Alex Wyatt has been awarded a CIHR Project Grant totaling $1,005,976 to support research on circulating tumor DNA (ctDNA) as an early biomarker of treatment response in metastatic castration-resistant prostate cancer (mCRPC). This...

The Vancouver Prostate Centre (VPC) is proud to announce that Dr. Yuzhuo Wang has been awarded two major research grants totaling over $1.26 million from the Canadian Institutes of Health Research (CIHR) to investigate the mechanisms driving aggressive and treatment-resistant prostate cancer. These...

Researchers at the Vancouver Prostate Centre have identified a previously unrecognized mechanism that enables prostate cancer to resist androgen deprivation therapy (ADT), one of the most common treatments for the disease. In a new study led by Dr. Xuesen Dong and published in the Journal of...